A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy Volunteers
Latest Information Update: 28 Mar 2022
At a glance
- Drugs SPH 3127 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 27 Feb 2021 Results of single and multiple ascending dose studies (NCT03128138 and NCT0325599), published in the Clinical Therapeutics
- 27 Feb 2021 Status changed from recruiting to completed, as per results published in the Clinical Therapeutics.
- 16 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.